These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31816156)

  • 1. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
    Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
    Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
    Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
    Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
    Oh SY; Kim DY; Kim YB; Suh KW
    World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
    Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
    Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
    Zaanan A; Taieb J
    Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
    Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
    BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
    Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
    Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
    J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
    Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
    Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
    Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
    Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
    Srdjan M; Jadranka A; Ivan D; Branimir Z; Daniela B; Petar S; Velimir M; Zoran K
    Indian J Med Res; 2016 May; 143(Supplement):S104-S111. PubMed ID: 27748284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.